Supernus Pharmaceuticals

Pioneering New Medicines in Neurology and Psychiatry With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. In 2013 we launched Oxtellar XR® and Trokendi XR®, two novel neurology products for the treatment of epilepsy. We are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2005
Size (employees)
344 (est)
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, US

Key People at Supernus Pharmaceuticals

Jack A. Khattar

Jack A. Khattar

President and CEO

Supernus Pharmaceuticals Office Locations

Supernus Pharmaceuticals has an office in Rockville
Rockville, US (HQ)
1550 E Gude Dr

Supernus Pharmaceuticals Metrics

Supernus Pharmaceuticals Financial Metrics

Revenue (2016)

$215 m

Revenue growth (2015-16), %

49%

Gross profit

$203 m

Gross profit margin (2016), %

94%

Net income (2016)

$91.2 m

Market capitalization (10-Mar-2017)

$1.3 b

Closing share price (10-Mar-2017)

$27.4

Cash (31-Dec-2016)

$66.4 m
Supernus Pharmaceuticals's current market capitalization is $1.3 b.
Supernus Pharmaceuticals's revenue was reported to be $215 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$12 m$122 m$144.4 m$215 m

Revenue growth, %

915%18%49%

Cost of goods sold

$1.1 m$5.8 m$8.4 m$12 m

Gross profit

$10.9 m$116.3 m$136 m$203 m

Gross profit Margin, %

91%95%94%94%

Operating expense total

$72.8 m$92.1 m$118.3 m$160.8 m

EBIT

($61.9 m)$24.2 m$17.7 m$54.2 m

EBIT margin, %

(515%)20%12%25%

Interest expense

$7.8 m$5 m$1.2 m$543 k

Interest income

$299 k$348 k$643 k$1.5 m

Income tax expense

$956 k($40.9 m)

Net Income

($92.3 m)$19.9 m$14 m$91.2 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$33 m$36.4 m$34.2 m$66.4 m

Accounts Receivable

$5.1 m$17.3 m$25.9 m$41.5 m

Inventories

$7.2 m$3.8 m$5.3 m$3 m

Current Assets

$97.2 m$108.9 m$106 m$151.4 m

PP&E

$2.6 m$2.4 m$3.9 m$4.3 m

Total Assets

$111 m$137.5 m$188.7 m$309.6 m

Accounts Payable

$18.3 m$1.9 m$4.3 m$8.1 m

Current Liabilities

$26.4 m$27.5 m$56.1 m$80.7 m

Additional Paid-in Capital

$212 m$230.1 m$264 m$276.1 m

Retained Earnings

($178.5 m)($158.7 m)($144.6 m)($84.3 m)

Total Equity

$33.5 m$71.4 m$118.9 m$191.8 m

Financial Leverage

3.3 x1.9 x1.6 x1.6 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($92.3 m)$19.9 m$14 m$91.2 m

Depreciation and Amortization

$742 k$928 k$921 k$2.4 m

Accounts Receivable

($5 m)($12 m)($8.6 m)($16 m)

Inventories

($6 m)($6.3 m)$854 k($4.2 m)

Accounts Payable

$8.5 m($1.3 m)$2.1 m$3.5 m

Cash From Operating Activities

($57.9 m)$7.7 m$32.1 m$66.8 m

Purchases of PP&E

($2.1 m)($1.6 m)

Cash From Investing Activities

($12.1 m)($4.9 m)($36.2 m)($36 m)

Cash From Financing Activities

$62.7 m$570 k$1.9 m$2.1 m

Interest Paid

$2.9 m$825 k$493 k

Supernus Pharmaceuticals Market Value History

Supernus Pharmaceuticals Company Life

You may also be interested in